Personalizing cancer immunotherapy

BrightPath, formerly known as GreenPeptide, is moving beyond peptides to push the boundaries of cancer immunotherapy toward more personalized treatments.

Like Comment
Page of
Go to the profile of Brightpath Biotherapeutics

Brightpath Biotherapeutics

BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.

No comments yet.